Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GeRX-681
- Development stage
- Preclinical
- Lead developer
- Gelteq
- Modality
- Hydrogel Systems → Drug Delivery Systems
- Administration
- Oral
01
Overview
GeRX-681 is an oral gel formulation in development by Gelteq for the treatment of gastroesophageal reflux disease (GERD). The therapeutic candidate utilizes Gelteq's proprietary gel-based delivery platform, which is designed to improve patient compliance, ease of swallowing (particularly for patients with dysphagia), and the bioavailability of active pharmaceutical ingredients. GeRX-681 is currently in the optimization phase of development.
- Other names
- GeRx-681GeRx681GeRx 681
Beyond the preview
Go deeper on GeRX-681.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GeRX-681.